Literature DB >> 11950153

Gene transfer and metabolic modulators as new therapies for pulmonary hypertension. Increasing expression and activity of potassium channels in rat and human models.

E D Michelakis1, J R Dyck, M S McMurtry, S Wang, X C Wu, R Moudgil, K Hashimoto, L Puttagunta, S L Archer.   

Abstract

UNLABELLED: Chronic Hypoxic Pulmonary Hypertension (CH-PHT) is characterized by pulmonary artery (PA) vasoconstriction and cell proliferation/hypertrophy. PA smooth muscle cell (PASMC) contractility and proliferation are controlled by cytosolic Ca++ levels, which are largely determined by membrane potential (E(M)). E(M) is depolarized in CH-PHT due to decreased expression and functional inhibition of several redox-regulated, 4-aminopyridine (4-AP) sensitive, voltage-gated K+ channels (Kv1.5 and Kv2.1). Humans with Pulmonary Arterial Hypertension (PAH) also have decreased PASMC expression of Kv1.5 and Kv2.1. We speculate this "K+-channelopathy" contributes to PASMC depolarization and Ca++ overload thus promoting vasoconstriction and PASMC proliferation. We hypothesized that restoration of Kv channel expression in PHT and might eventually be beneficial.
METHODS: Two strategies were used to increase Kv channel expression in PASMCs: oral administration of a metabolic modulator drug (Dichloroacetate, DCA) and direct Kv gene transfer using an adenovirus (Ad5-Kv2.1). DCA a pyruvate dehydrogenase kinase inhibitor, promotes a more oxidized redox state mimicking normoxia and previously has been noted to increase K+ current in myocytes. Rats were given DCA in the drinking water after the development of CH-PHT and hemodynamics were measured approximately 5 days later. We also tested the ability of Ad5-Kv2.1 to increase Kv2.1 channel expression and function in human PAs ex vivo.
RESULTS: The DCA-treated rats had decreased PVR, RVH and PA remodeling compared to the control CH-PHT rats (n=5/group, p<0.05). DCA restored Kv2.1 expression and PASMC Kv current density to near normoxic levels. Adenoviral gene transfer increased expression of Kv2.1 channels and enhanced 4-AP constriction in human PAs.
CONCLUSION: Increasing Kv channel function in PAs is feasible and might be beneficial.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11950153     DOI: 10.1007/978-1-4757-3401-0_26

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

Review 1.  Oxidation of KCNB1 K(+) channels in central nervous system and beyond.

Authors:  Federico Sesti; Xilong Wu; Shuang Liu
Journal:  World J Biol Chem       Date:  2014-05-26

2.  miR-1 is increased in pulmonary hypertension and downregulates Kv1.5 channels in rat pulmonary arteries.

Authors:  Gema Mondejar-Parreño; María Callejo; Bianca Barreira; Daniel Morales-Cano; Sergio Esquivel-Ruiz; Laura Moreno; Angel Cogolludo; Francisco Perez-Vizcaino
Journal:  J Physiol       Date:  2018-06-21       Impact factor: 5.182

Review 3.  Molecular and functional significance of Ca(2+)-activated Cl(-) channels in pulmonary arterial smooth muscle.

Authors:  Normand Leblanc; Abigail S Forrest; Ramon J Ayon; Michael Wiwchar; Jeff E Angermann; Harry A T Pritchard; Cherie A Singer; Maria L Valencik; Fiona Britton; Iain A Greenwood
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

4.  Ezrin Regulating the Cytoskeleton Remodeling is Required for Hypoxia-Induced Myofibroblast Proliferation and Migration.

Authors:  Bin Yi; Lin Chen; Jing Zeng; Jian Cui; Guansong Wang; Guisheng Qian; Karine Belguise; Xiaobo Wang; Kaizhi Lu
Journal:  Front Cardiovasc Med       Date:  2015-03-03

Review 5.  Molecular and Genetic Profiling for Precision Medicines in Pulmonary Arterial Hypertension.

Authors:  Shahood Fazal; Malik Bisserier; Lahouaria Hadri
Journal:  Cells       Date:  2021-03-13       Impact factor: 7.666

Review 6.  Important Functions and Molecular Mechanisms of Mitochondrial Redox Signaling in Pulmonary Hypertension.

Authors:  Jorge Reyes-García; Abril Carbajal-García; Annarita Di Mise; Yun-Min Zheng; Xiangdong Wang; Yong-Xiao Wang
Journal:  Antioxidants (Basel)       Date:  2022-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.